Sarwar, Muhammad Rehan https://orcid.org/0000-0003-4312-9157
McDonald, Vanessa Marie https://orcid.org/0000-0001-9890-3408
Abramson, Michael J. https://orcid.org/0000-0002-9954-0538
Wilson, Sally
Holland, Anne E.
Bonevski, Billie https://orcid.org/0000-0001-8505-622X
Mahal, Ajay
Paul, Eldho https://orcid.org/0000-0003-1263-7255
Meier, Brian
George, Johnson https://orcid.org/0000-0002-0326-0495
Funding for this research was provided by:
Monash University
Article History
Received: 1 August 2024
Accepted: 7 October 2024
First Online: 28 October 2024
Change Date: 13 November 2024
Change Type: Update
Change Details: The original online version of this article was revised: the corresponding author Johnson George's affiliation has been corrected as Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Change Date: 22 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11096-024-01835-6
Conflicts of interests
: MJA holds investigator-initiated grants for unrelated research from Pfizer, Boehringer Ingelheim, Sanofi and GSK. He has also undertaken an unrelated consultancy (paid to his employer) for Sanofi and received a speaker’s fee from GSK. VM has received research funding from AstraZeneca, Cyclopharm, GSK, NHMRC, and Ramaciotti; speaker’s honoraria from AstraZeneca, Boehringer Ingelhiem, and GSK; and provided consultancy for AstraZeneca, GSK, and Menarini. JG holds investigator-initiated grants for unrelated research from Pfizer, GSK and Boehringer Ingelheim. He has received honoraria (paid to his employer) from a consultancy for GSK, AstraZeneca and for invited presentations at a continuing education event organised by Pfizer. The other authors declare no conflicts of interest.